FDA updates draft guidance to set a clear path for the nonproprietary naming of interchangeable biosimilars.
Read more: Statement from FDA Commissioner Scott Gottlieb, M.D., on FDA’s steps on naming of biological medicines to balance competition and safety for patients receiving these products